

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Previously presented) A method of expanding a population of stem or progenitor cells, the method comprising steps of:
providing at least one stem or progenitor cell with less than wild type p21 activity; and
expanding the cell population.
2. (Previously presented) The method of claim 1, wherein the step of providing comprises:
providing a stem or progenitor cell; and
disrupting the cell's p21 gene.
3. (Previously presented) The method of claim 1, wherein the step of providing comprises:
providing a stem or progenitor cell; and
contacting the cell with an agent, wherein the agent inhibits p21 activity.
4. (Previously presented) A method of expanding a population of cells, the method comprising the steps of:
providing at least one stem or progenitor cell with less than wild type p27 activity and less than wild type p21 activity; and
expanding the cell population.
5. (Original) The method of claim 4, wherein the step of providing comprises:
providing a cell; and

disrupting p27 and p21 genes.

6. (Original) The method of claim 4, wherein the step of providing comprises:
providing a cell; and
contacting the cell with an agent, wherein the agent inhibits p27 and p21 activity.
7. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a stem cell.
8. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a hematopoietic stem cell.
9. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a hematopoietic progenitor cell.
10. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is an erythropoietic cell.
11. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a granulopoietic cell.
12. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a thrombopoietic cell.
13. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a neural cell.
14. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is selected from the group consisting of renal cell, gastrointestinal cell, hepatic cell, skin cell, lung cell, muscle cell, and cardiac muscle cell.

15. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is an adult-derived stem cell.
16. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is an embryonically derived stem cell.
17. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a pluripotent stem cell.
18. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a multi-potential stem cell.
19. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a fetal cell.
20. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is an embryonic cell.
21. (Currently amended) The method of claim 1 ~~or~~ 4, wherein the cell is a mesenchymal cell.
22. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is a protein.
23. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is a peptide.
24. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is a polynucleotide.
25. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is a chemical compound.
26. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is an antibody or fragment thereof.

27. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is an antisense agent.
28. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is a triple helix forming agent.
29. (Currently amended) The method of claim 3 ~~or~~ 6, wherein the agent is an aptamer.
30. (Previously presented) A stem or progenitor cell with less than wild type p21 activity.
31. (Previously presented) A stem or progenitor cell with at least one copy of the p21 gene disrupted.
32. (Previously presented) A stem or progenitor cell with both copies of the p21 gene disrupted.
33. (Canceled)
34. (Original) A cell with at least one copy of the p27 gene disrupted.
35. (Original) A cell with at least one copy of the p27 gene and p21 gene disrupted.
36. (Original) The cell of claim 30, wherein the cell is a stem cell.
37. (Original) The cell of claim 30, wherein the cell is a progenitor cell.
38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Canceled)

42. (Original) A pharmaceutical composition comprising a therapeutically effective amount of cells of claim 30.

43. (Original) A pharmaceutical composition comprising a therapeutically effective amount of stem cells of claim 36.

44. (Original) A pharmaceutical composition comprising a therapeutically effective amount of progenitor cells of claim 37.

45. (Original) A pharmaceutical composition comprising a therapeutically effective amount of cells of claim 30, and a pharmaceutically acceptable excipient.

46-74. (Canceled)

75. (Currently amended) The method of claim 3 ~~or 6~~, wherein the agent is an RNA inhibiting agent.